4-Ethyl-2-propylthiazole | 41981-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Ethyl-2-propylthiazole
• 英文别名: 4-ethyl-2-propyl-1,3-thiazole
• CAS: 41981-68-4
• 化学式: C₈H₁₃NS
• 分子量: 155.26
• InChiKey: PMIYYESQWZHQKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  213.3±9.0 °C(Predicted)
• 密度：
  1.006±0.06 g/cm3(Predicted)
• 保留指数：
  1190

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：US20180221279A1

  公开（公告）日：2018-08-09

  Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.

  本文提供了适用于装载到脂质体纳米粒载体中的药物衍生物。在一些首选方面，这些衍生物包括一种水溶性较差的药物衍生物，其与一种弱碱基团衍生化，有助于通过LN跨膜pH或离子梯度将药物活性地装载到LN的水相内部。弱碱基团可以选择性地包括一个亲脂性结构域，有助于将药物活性地装载到脂质体膜的内单分子层。优点是，药物衍生物的LN配方相对于相应的游离药物表现出改善的溶解度、降低的毒性、增强的疗效和/或其他优点。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• Modified Drugs for Use in Liposomal Nanoparticles
  申请人：Cullis Peter

  公开号：US20110165225A1

  公开（公告）日：2011-07-07

  Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.

  本文提供了适用于载入脂质体纳米粒子载体的拖曳导数。在某些优选方面，这些导数包括一种难溶于水的拖曳经过弱碱基团衍生化，该弱碱基团促进通过LN跨膜pH或离子梯度将拖曳活性负载到LN的水内部。弱碱基团可以选择包括一个亲脂性域，该亲脂性域促进将拖曳活性负载到脂质体膜的内单层。优点是，与相应的自由拖曳相比，拖曳导数的LN配方表现出改善的溶解度、降低的毒性、增强的功效和/或其他益处。
• HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS
  申请人：Arndt Joseph

  公开号：US20120208819A1

  公开（公告）日：2012-08-16

  The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

  本发明提供了作为PDK1抑制剂有用的化合物。本发明还提供了它们的组合物，以及治疗PDK1介导的疾病的方法。
• PPAR AGONISTS
  申请人：Salk Institute for Biological Studies

  公开号：US20160023991A1

  公开（公告）日：2016-01-28

  Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

  本文提供了一些化合物和组合物，可用于增加PPARδ活性。这些化合物和组合物可用于治疗与PPARδ相关的疾病（例如肌肉疾病、血管疾病、脱髓鞘疾病和代谢性疾病）。

表征谱图